Node negative breast câncer: evaluation ofprognostic factors and immunohistochemical markers (estrogen receptor; P53 and HER-2)
Keywords:
Breast cancer, Node negative, Prognostic factors, Oncogen her-2, Suppressor gene P53Abstract
High incidence, devastating consequences on mental and organic hea/th and high morta/ity
rates characterize breast câncer as a serious world hea/th prob/em. The heterogeneous aspects
ofthe disease associated with poor prognosis have encouraged the study of pathoiogicai and
biological factors which allow us to understand the behavior of breast câncer better. Nodenegative breast câncer patients ha ve presented a higher o veraii survivai rates when compared
to node-positive patients. However, approximate/y 30% of node-negative patients have
presented worse prognosis associated with câncer recurrence. Fifty-four node-negative patients
have been retrospectively evaiuated for clinicaiand pathoiogicai data and correiated to estrogen
receptor, tumor suppressor gene P53 and oncogene HER-2 expression. The average age ofthe
women was 57 years (range 25-80) and the average tumor size was 3.42 cm (range 1-20).
Associations between severa! anatomic, pathoiogicai and immunohistochemical factors have
been analyzed and statistical significance was observed between tumor size and morta/ity,
tumor size and incidence of metastasis, histoiogicai grade and estrogen receptor expression,
tumor suppressor gene P53 expression and estrogen receptor expression, disease free survivai
(DFS) and histoiogicai grade, DFS and incidence ofmetastasis, DFS and P53 expression, overall
survivai and tumor size, and overall survivai and incidence of metastasis.
Downloads
References
1.GASPARINI G, POZZA F, HARRIS AL.
Evaluating the potential usefulness of
new prognostic and predictive indicators
in node-negative breast câncer patients.
J Natl Câncer Inst 1993; 85: 1206-19.
2.WEIDNER N. Prognostic factors in breast
carcinoma. Current Opinion in Obstetrics
and Gynecology 1995; 7: 4-9.
3.BLOOM HJG, RICHARDSON WW. Histologic
grading and prognosis in breast câncer:
A study of 1.709 cases of which 359
have been followed for 15 years. Br J Câncer 1957; 2: 353-77.
4.MIRZA AN, MIRZA NQ, VLASTOS G,
SINGLETARY SE. Prognostic factors in
node-negative breast câncer: a review
of studies with sample size more than
200 and follow-up more than 5 years. Ann Surg 2002; 235: 10-26.
5.UEMURAG. Estudo anatomodínico do carcinoma ductal invasivo em pacientes
axila-negativas associado à identificação
dos receptores de estrogênio. [dissertação] Botucatu: Faculdade de Medicina, Universidade Estadual Paulista; 1998.
6.CORADINI D, DAIDONE MG, BORACCHI
P et a! Time-dependent relevance of
steroid receptors in breast câncer. J Clin Oncol 2000; 18: 2702-9.
7.HAMILTON A, PICCART M. The contribution
of molecular markers to the prediction of
response in the treatment of breast câncer:
a review of the literatura on HER-2, p53
and BCL-2. Ann Oncol 2000; 11: 647-63.
8.VOLPI A, DE PAOLA F, NANNI O et a!
Prognostic significance of biologic markers in node-negative breast câncer
patients: a prospective study. Breast
Câncer Res Treat 2000; 63: 181-92.
9.EISENBERG AL, KOIFMAN S. Marcadores
tumorais. Revista Brasileira de
Cancerologia 2001; 47: 377-88.
10.ANDERSON WF, CHU KC, CHATTERJEE N, BRAWLEY O, BRINTON LA. Tumor
variants by hormone receptor
expression in white patients with nodenegative breast câncer from the
surveillance, epidemiology, and end
results database. J Clin Oncol 2001; 19:
18-27.
11.EISENBERG ALA, KOIFMAN S, REZENDE
LMMC. Receptores hormonais: associação com fatores prognósticos para câncer de mama. Revista Brasileira de
Cancerologia 2001, 47: 49-58.
12.JANSSON T, INGANAS M, SJOGREN S et
al. P53 status predicts survival in breast
câncer patients treated with or without
postoperative radiotherapy: a novel
hypothesis based on clinicai findings. J Clin Oncol 1995; 13: 2745-51.
13.NOGUCHI S, KOYAMA H, KASUGAI T
et al. The possible prognostic
significance of P53 immunostaining
status of the primary tumor in patients
developing local recurrence after
breast-conserving surgery. Oncology
1998; 55: 450-5.
14.OVERGAARD J, YILMAZ M, GULDBERG
P, HANSEN LL, ALSNERJ. TP53 mutation
is an independent prognostic marker for
pooroutcome in both node-negative and
node-positive breast câncer. Acta Oncol
2000; 39: 327-33.
15.FERRERO JM, RAMAIOLI A, FORMENTO
JL et a/. P53 determination alongside
classical prognostic factors in nodenegative breast câncer: an evaluation
at more than 10-year follow-up. Ann Oncol 2000; 11: 393-7.
16.IOAKIM-LIOSSI A, KARAKITSOS P, MARKOPOULOS C et al. P53 protein
expression and estrogen and
progesterone receptor status in invasive
ductal breast carcinomas. Cytopathology
2001; 12: 197-202.
17.ZHENG WQ, LU J, ZHENG JM, HU FX, NI
CR. Variation of ER status between
primary and metastatic breast câncer
and relationship to P53 expression.
Steroids 2001; 66: 905-10.
18.QUENEL N, WAFFLART }, BONICHON F
et aI. The prognostic value of c-erbB2
in primary breast carcinomas: a study
on 942 cases. Breast Câncer Res Treat
1995; 35: 283-91.
19.KORKOLIS D, ARDAVANIS A, YOTIS J, KYROUDI A, GORGOULIS V, KITTAS C. HER-2/neu overexpression in breast
câncer: an immunohistochemical study
including correlations with
clinicopathologic parameters, P53
oncoprotein and cathepsin-D. Anticancer
Res 2001; 21: 2207-12.
20.MENARD S, FORTIS S, CASTIGLIONI
F, AGRESTI R, BALSARI A. HER2 as
a prognostic factor in breast câncer.
Oncology 2001; 61(suppl.) 2:
67-72.
21.NAKOPOULOU LL, ALEXIADOU A,
THEODOROPOULOS GE, LAZARIS AC,
TZONOU A, KERAMOPOULOS A.
Prognostic significance of the coexpression of p53 and c-erbB-2 proteins
in breast câncer. J Pathol 1996; 179:
31-8.
22.GODOY AB, NETO MM., LOGULLO AF et
at. Prediction of outcome in early stage
primary breast câncer by c-erbB-2 and
P53 immunostaing. Breast Câncer Res
Treat 2001; 69: 266.
23.BEENKEN SW, GRIZZLE WE, CROWE DR
et a! Molecular biomarkers for breast
câncer prognosis: coexpression of cerbB-2 and P53. Ann Surg 2001; 233:
630-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Gilberto Uemura, laurival A. De Luca, losé Ricardo P. Rodrigues, Heloísa M. Vespoli, Lídia Raquel de Carvalho, Paulo Traiman
This work is licensed under a Creative Commons Attribution 4.0 International License.
